| Insiders | Shares | % | Avg Price | Total $ | |
|---|---|---|---|---|---|
| Buys | 1 | +2.56M | 97.7% | $10.64 | +$27.2M |
| Sells | 2 | -60K | 2.3% | $17.33 | -$1.04M |
| Net | -1 | +2.5M | 95.4% | +$26.2M |
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | Director, 10%+ Owner | $97.7M | +$27.2M | +38.6% | Jun 20, 2024 |
| Oxford Science Enterprises plc | 10%+ Owner | $57.1M | May 10, 2022 | ||
| James E. Flynn | Possible Member of 10% Group, 10%+ Owner | $3.97M | May 10, 2022 | ||
| James G. McArthur | President and CEO, Director | $7.06K | Mar 1, 2024 | ||
| Niels Svenstrup | SVP, Chem. Mfg & Controls | $0 | -$134K | -100% | May 17, 2024 |
| Michelle L. Mellion | Chief Medical Officer | $0 | -$906K | -100% | Jul 24, 2024 |
| Joshua Resnick | Director | Jun 20, 2024 | |||
| Paul Streck | EVP, Head of R&D | Aug 19, 2024 | |||
| Heidi Henson | Director | Jun 20, 2024 | |||
| Laurie Keating | Director | Jun 20, 2024 | |||
| Mary Beth DeLena | General Counsel | Jan 15, 2024 | |||
| Habib J. Dable | Director | Jun 20, 2024 | |||
| Sonia Bracegirdle | Sr. VP Strategy & Operations | May 6, 2022 | |||
| Christopher Ashton | Director | Jun 20, 2024 | |||
| Noel Donnelly | Chief Financial Officer | Mar 1, 2024 | |||
| Jaya Goyal | EVP, Res. & Preclin. Dev. | Mar 24, 2023 | |||
| Howard Mayer | Director | Jun 20, 2024 |
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|